Bostick-Bruton F - Search Results

1

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Dabholkar M, et al. J Clin Invest. 1994 Aug;94(2):703-8. doi: 10.1172/JCI117388. J Clin Invest. 1994. PMID: 8040325 Free PMC article.

2

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. Dabholkar M, et al. J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7. doi: 10.1093/jnci/84.19.1512. J Natl Cancer Inst. 1992. PMID: 1433335

3

Suramin in advanced platinum-resistant ovarian cancer.

Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Reed E, et al. Eur J Cancer. 1992;28A(4-5):864-6. doi: 10.1016/0959-8049(92)90135-o. Eur J Cancer. 1992. PMID: 1524910 Clinical Trial.

4

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Parker RJ, et al. J Clin Invest. 1991 Mar;87(3):772-7. doi: 10.1172/JCI115080. J Clin Invest. 1991. PMID: 1999494 Free PMC article.

5

Expression of excision repair genes in non-malignant bone marrow from cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E. Dabholkar M, et al. Mutat Res. 1993 Jan;293(2):151-60. doi: 10.1016/0921-8777(93)90066-p. Mutat Res. 1993. PMID: 7678143

6

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Reed E, et al. Cancer Res. 1993 Aug 15;53(16):3694-9. Cancer Res. 1993. PMID: 8339278 Clinical Trial.

7

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Parker RJ, et al. Cancer Res. 1993 Jan 15;53(2):242-7. Cancer Res. 1993. PMID: 8417816

8

Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.

Dabholkar MD, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, Yu JJ, Silber JR, Reed E. Dabholkar MD, et al. Mol Carcinog. 1996 Sep;17(1):1-7. doi: 10.1002/(SICI)1098-2744(199609)17:1<1::AID-MC1>3.0.CO;2-M. Mol Carcinog. 1996. PMID: 8876669

9

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E. Yu JJ, et al. Mutat Res. 1997 Sep;382(1-2):13-20. doi: 10.1016/s1383-5726(97)00004-6. Mutat Res. 1997. PMID: 9360634

10

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.

Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, Reed E. Li Q, et al. Among authors: bostick bruton f. Int J Oncol. 1998 Nov;13(5):987-92. doi: 10.3892/ijo.13.5.987. Int J Oncol. 1998. PMID: 9772291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters